top of page

ASCO 2026: Immuneering presented an update of the P2 trial of its deep cyclic inhibitor of MEK in 1L pancreatic cancer at ASCO. CEO Ben Zeskind argues why competitor data should not overshadow this

  • 21 hours ago
  • 1 min read

He describes the data, which showed a 17.3 months median OS in 55 patients vs. 8.5 months for SoC, and descrbies why he believes the therapy has an ideal profile for first line patients. A phase three study is already active and accruing patients.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page